SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is a hot topic following its announcement of a strategic manufacturing partnership designed to scale production of its fingerprinting drug screening reader and reduce costs. The market is heavily divided, with many anticipating explosive gains due to the stock's low float, while others express significant concern over recent share dilution from a private placement with warrants. This has created extremely volatile trading activity, as bullish momentum traders clash with short-sellers over the stock's immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is a key topic as it actively positions itself for the substantial Rural Health Transformation Program, aiming to modernize rural healthcare with its virtual care network and AI-driven solutions. Investors are vocal, with some passionately highlighting the company's global leadership and significant undervaluation, expecting a major turnaround, while others voice deep frustration over past stock performance and current management's perceived shortcomings. Recent discussions also revolve around strategic partnerships, such as the TytoCare integration for at-home care, as potential catalysts.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Widespread speculation about a potential SpaceX initial public offering is driving significant market conversation and creating considerable buzz within the aerospace sector. This anticipation is fueling active community discussion around related companies positioned as 'SpaceX IPO plays' or partners, notably highlighting firms involved in upcoming Falcon 9 missions. However, alongside the excitement, some investors are raising cautionary flags about speculative mentions and the legitimacy of certain 'SPACEX CRYPTO' references.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention for its expanding anticoagulation pipeline, highlighted by recent acquisitions and significant progress on its lead candidate, tecarfarin, including manufacturing readiness and a collaboration with Abbott. This "quiet expansion" is sparking community interest, with many anticipating a breakout given its low float and regulatory designations. However, skepticism persists among some regarding the company's financial stability and potential dilution.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is a hot topic following a substantial $600 million financing boost and the looming 1-for-30 reverse stock split, which has sparked intense debate among investors. While many are optimistic about strong Q4 delivery numbers for the Polestar 4 and new Google Gemini AI integration, community sentiment remains sharply divided on whether operational improvements can finally overcome persistent skepticism about the stock's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Equity

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate, SP-102, is a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain. The company is headquartered in Palo Alto, CA.

DECA
Denali Capital Acquisition Corp - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest DECA News

DECADenali Capital Acquisition Corp - Ordinary Shares - Class A